Improvements in lung function in Phase 3 studies

29 November 2018

Exciting news – Vertex has announced that studies involving a triple combination treatment significantly improved lung function in people with the ddf508 mutation (the most common mutation).

This has massive implications for many people with cystic fibrosis, and we'll be following the continued development of the treatment closely.

It also highlights the importance of the Kalydeco campaign to get Kalydeco publicly funded. Vertex manufactures Kalydeco, so in order to access its other treatments we first need Kalydeco funded and available.

Keep up to date with the Kalydeco campaign.